



PANELS/PROFILES

PANELS/PROFILES

HNL offers groups of tests defined as panels by the American Medical Association Current Procedural Terminology (CPT), as well as profiles based on acceptable clinical practice.

The following are the more commonly ordered Panels/Profiles. Additional Panels/Profiles offered by HNL can be found in the Alphabetical Test Listing section. The Office of Inspector General (OIG) of the United States Department of Health and Human Services has addressed the offering of customized profiles in their Model Compliance Plan for Laboratories. The plan stresses the importance of clear communication between laboratories and ordering physicians regarding information involving payment ramifications for ordering tests in profiles rather than on an individual test basis.

If you use HNL customized packages, a Custom Package Acknowledgement Form which addresses items such as the profile components, Medicare reimbursement amounts, and medical necessity, will be sent to you for your review and signature on an annual basis. All components of AMA panels and HNL profiles may also be ordered individually.

| Test Name | Order Code |
|--|---|
| Adenovirus Antibody | ADVAB |
| Includes: | Total Adenovirus Antibody |
| Suggest CPT coding: | 86603 |
| Methodology: | Complement Fixation |
| Testing Schedule: | Routine, Monday–Friday no holidays |
| Report Available: | 3–5 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. |
| Reference Range: | <1:8 |
| Clinical Utility: | Useful for diagnosis of Adenovirus Infections. Single titers > 1:64 are indicative of recent or current infection. Titers of 1:8–1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. |

| Test Name | Order Code |
|---------------------------------|--|
| Allergen Profile, Asthma | ASMPR |
| Includes: | Total IgE along with the following specific IgE allergens: <ul style="list-style-type: none"> • Molds: Alternaria alternata, Aspergillus fumigatus, Candida albicans, Cladosporium herbarium, Mucor racemosus • Miscellaneous: Cat dander, Dog dander, Cockroach, Common ragweed, Timothy grass, Oak, House dust mites: D. farinae and D. pteronyssius |
| Suggest CPT coding: | 82785,86003(x13) |
| Methodology: | ImmunoCAP (FEIA) |
| Testing Schedule: | Routine, 4–6 times per week |
| Report Available: | 3–7 days |
| Minimum Volume: | 4 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Reference Range: | <ul style="list-style-type: none"> • Total IgE: See individual test listing • Specific IgE Allergens: See order code ALKIT |
| Critical Values: | Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |

| Test Name | Order Code |
|--|--|
| Allergen Profile, Atopic Dermatitis | ADMPR |
| Includes: | Total IgE along with the following specific IgE allergens: <ul style="list-style-type: none"> • Foods: Egg white, Fish (Cod), Milk, Peanut, Soybean, Wheat • Miscellaneous: Cat dander, Alternaria alternata, House dust mite (D. farinae), Common ragweed, Timothy grass, Oak, Staphylococcal Enterotoxins A and B. |
| Suggest CPT coding: | 82785,86003(x14) |
| Methodology: | ImmunoCAP (FEIA) |
| Testing Schedule: | Routine, 4–6 times per week |

Continued...

| Test Name | Order Code |
|--|---|
| Allergen Profile, Atopic Dermatitis | ADMPR |
| Report Available: | 3–7 days |
| Minimum Volume: | 4 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Reference Range: | <ul style="list-style-type: none">• Total IgE: See individual test listing• Specific IgE Allergens: See order code ALKIT |
| Clinical Utility: | Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |

| Test Name | Order Code |
|--------------------------------------|---|
| Allergen Profile, Food, Basic | FODPR |
| Alternate Name: | Food Allergen Profile, Basic |
| Includes: | Total IgE along with the following specific IgE allergens: <ul style="list-style-type: none">• Chicken, Clam, Corn (Maize), Egg White, Fish (Cod), Milk, Peanut, Shrimp, Soybean, Tomato, Walnut, Wheat |
| Suggest CPT coding: | 82785,86003(x12) |
| Methodology: | ImmunoCAP (FEIA) |
| Testing Schedule: | Routine, 4–6 times per week |
| Report Available: | 3–5 days |
| Minimum Volume: | 4 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Reference Range: | <ul style="list-style-type: none">• Total IgE: See individual test listing• Specific IgE Allergens: See order code ALKIT |
| Clinical Utility: | Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |

| Test Name | Order Code |
|------------------------------------|--|
| Allergen Profile, Food, Nut | NUTPR |
| Alternate Name: | Food Allergen Profile, Nut |
| Includes: | Total IgE along with the following specific IgE allergens: <ul style="list-style-type: none">• Almond, Brazilnut, Cashew, Hazelnut, Peanut, Pecan, Pistachio, Walnut |
| Suggest CPT coding: | 82785,86003(x8) |
| Methodology: | ImmunoCAP (FEIA) |
| Testing Schedule: | Routine, 4–6 times per week |
| Report Available: | 3–5 days |
| Minimum Volume: | 4 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Reference Range: | <ul style="list-style-type: none">• Total IgE: See individual test listing• Specific IgE Allergens: See order code ALKIT |

Continued...

| Test Name | | Order Code |
|------------------------------------|--|-------------------|
| Allergen Profile, Food, Nut | | NUTPR |
| Clinical Utility: | Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. | |

| Test Name | | Order Code |
|--|--|-------------------|
| Allergen Profile, Food, Shellfish | | SHLPR |
| Includes: | Total IgE along with the following specific IgE allergens: <ul style="list-style-type: none">• Blue Mussel, Clam, Crab, Fish (Cod), Lobster, Scallop, Shrimp, Tuna | |
| Suggest CPT coding: | 82785,86003(x8) | |
| Methodology: | ImmunoCAP (FEIA) | |
| Testing Schedule: | Routine, 4–6 times per week | |
| Report Available: | 3–5 days | |
| Minimum Volume: | 4 mL serum | |
| Container: | 2 Gold top tubes, <u>serum separator</u> | |
| Reference Range: | <ul style="list-style-type: none">• Total IgE: See individual test listing• Specific IgE Allergens: See order code ALKIT | |
| Clinical Utility: | Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. | |

| Test Name | | Order Code |
|---------------------------------------|--|-------------------|
| Allergen Profile, Otitis Media | | OTMPR |
| Includes: | Total IgE along with the following specific IgE allergens: <ul style="list-style-type: none">• Foods: Chicken, Corn (Maize), Egg White, Fish (Cod), Milk, Peanut, Soybean, Tomato, Wheat• Miscellaneous: Cat dander, Alternaria alternata, House dust mite (D. farinae), Common ragweed, Timothy grass, Oak | |
| Suggest CPT coding: | 82785,86003(x15) | |
| Methodology: | ImmunoCAP (FEIA) | |
| Testing Schedule: | Routine, 4–6 times per week | |
| Report Available: | 3–5 days | |
| Minimum Volume: | 4 mL serum | |
| Container: | 2 Gold top tubes, <u>serum separator</u> | |
| Reference Range: | <ul style="list-style-type: none">• Total IgE: See individual test listing• Specific IgE Allergens: See order code ALKIT | |
| Clinical Utility: | Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. | |

| Test Name | | Order Code |
|--------------------------------|---|-------------------|
| Allergen Profile, Venom | | VENPR |
| Includes: | Total IgE along with the following specific IgE allergens: <ul style="list-style-type: none">• Common Wasp/Yellow Jacket, European Hornet, Honey Bee, Paper Wasp, Yellow Hornet, White faced Hornet | |
| Suggest CPT coding: | 82785,86003(x6) | |
| Methodology: | ImmunoCAP (FEIA) | |

Continued...

| Test Name | Order Code |
|--------------------------------|---|
| Allergen Profile, Venom | VENPR |
| Testing Schedule: | Routine, 4–6 times per week |
| Report Available: | 3–5 days |
| Minimum Volume: | 4 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Reference Range: | <ul style="list-style-type: none">• Total IgE: See individual test listing• Specific IgE Allergens: See order code ALKIT |
| Clinical Utility: | Allergen specific IgE levels (kU/L) provide 95% Positive Predictive Values (PPV) for clinical reactivity to the specific allergen challenge. |

| Test Name | Order Code |
|--|--|
| Antinuclear Antibody Profile, Comprehensive | ANAP |
| Includes: | <ul style="list-style-type: none">• Antinuclear Antibody Screen (ANA)• DNA Autoantibody, Double Stranded• SS–A Autoantibody• SS–B Autoantibody• Sm\RNP Autoantibody• Sm Autoantibody• Scl–70 Autoantibody• Reflexed when appropriate:• Titer and pattern |
| Suggest CPT coding: | 86038,86225,86235(x5) |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine, 2 times per week |
| Report Available: | 4–7 days |
| Minimum Volume: | 2 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | DO NOT confuse with Antinuclear Antibody Screen (ANA). |
| Reference Range: | See individual test listings |
| Clinical Utility: | Comprehensive profile for initial evaluation of connective tissue disorders. |

| Test Name | Order Code |
|---------------------------------|--|
| Ashkenazi Jewish Profile | JEWMP |
| Includes: | <ul style="list-style-type: none">• Canavan Disease Mutation Analysis• Cystic Fibrosis Mutation Analysis• Familial Dysautonomia Mutation Analysis• Tay Sachs Enzyme Screen• Tay Sachs Mutation DNA |
| Suggest CPT coding: | 81200,81220,81255,81260,83080 |
| Methodology: | Fluorometric Enzymatic Assay and Polymerase Chain Reaction (PCR) |
| Testing Schedule: | Routine, Monday–Friday no holidays |
| Report Available: | 12–18 days |
| Minimum Volume: | 30 mL whole blood |
| Container: | 3 Yellow top tubes, <u>ACD Solution A</u> |

Continued...

| Test Name | | Order Code |
|--|---|-------------------|
| Ashkenazi Jewish Profile | | JEWMP |
| Collection: | Collect Monday–Friday ONLY before 1400, no holidays. | |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Specimens must arrive in the laboratory before 1600.• Store as whole blood in original tube at room temperature.• Must provide patient's ethnic background, family history, and diagnosis on Requisition Form. | |
| Reference Range: | See Patient Report | |
| Clinical Utility: | Individuals identified as or descended from Ashkenazi (eastern European) Jews are at increased risk for many autosomal recessive genetic diseases. Carrier screening is useful to identify couples who, if both are carriers of one of these diseases, have a 1 in 4 chance of transmitting these diseases to their children. | |

| Test Name | | Order Code |
|----------------------------------|--|-------------------|
| Bacterial Antigen Profile | | BACG |
| Alternate Name: | <ul style="list-style-type: none">• Bactigen Profile• Group B Strep Antigen, CSF• H, influenzae Type b antigen, CSF• Neisseria meningitides Antigen• Strep pneumoniae Antigen | |
| Includes: | <ul style="list-style-type: none">• Haemophilus influenzae Type β Antigen Detection• Neisseria meningitidis Antigen Detection (Groups A/Y and C/W135)• Group B/ E. coli K1 Ag• Streptococcus Group B, Antigen Detection• Streptococcus pneumoniae Antigen Detection | |
| Suggest CPT coding: | 86403(x5) | |
| Methodology: | Latex Agglutination | |
| Testing Schedule: | Routine, daily | |
| Report Available: | 3–5 days | |
| Minimum Volume: | 2 mL cerebrospinal fluid | |
| Container: | Sterile conical tube | |
| Reference Range: | Negative | |
| Clinical Utility: | An aid for the diagnosis of bacterial meningitis | |

| Test Name | | Order Code |
|------------------------------|---|-------------------|
| Basic Metabolic Panel | | BMP |
| Includes: | <ul style="list-style-type: none">• Calcium• Carbon dioxide (CO₂)• Chloride• Creatinine• Glucose• Potassium• Sodium• Urea nitrogen (BUN)• Anion Gap Calculation• Glomerular Filtration Rate Calculation (GFR) | |
| Suggest CPT coding: | 80048 | |
| Methodology: | See individual test listings | |
| Testing Schedule: | Routine daily, STAT testing available | |

Continued...

| Test Name | Order Code |
|------------------------------|---|
| Basic Metabolic Panel | BMP |
| Report Available: | 1 day |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listings. |
| Critical Values: | See individual test listings. |
| Clinical Utility: | Used to evaluate blood glucose; electrolyte, fluid and acid base balances, and kidney function. |

| Test Name | Order Code | | | | | | |
|---|--|------------------|--------------|------------------|--------------|------------------|----------------|
| Cardiolipin Autoantibody Profile | ACRD | | | | | | |
| Includes: | IgG, IgA and IgM Cardiolipin Autoantibodies | | | | | | |
| Suggest CPT coding: | 86147(x3) | | | | | | |
| Methodology: | Enzyme-Linked Immunosorbent Assay (ELISA) | | | | | | |
| Testing Schedule: | Routine, 1 time per week | | | | | | |
| Report Available: | 5-7 days | | | | | | |
| Minimum Volume: | 1 mL serum | | | | | | |
| Container: | Gold top tube, <u>serum separator</u> | | | | | | |
| Reference Range: | <table border="1"><tr><td>Cardiolipin IgG:</td><td><15 GPL U/mL</td></tr><tr><td>Cardiolipin IgA:</td><td><12 APL U/mL</td></tr><tr><td>Cardiolipin IgM:</td><td><12.5 MPL U/mL</td></tr></table> | Cardiolipin IgG: | <15 GPL U/mL | Cardiolipin IgA: | <12 APL U/mL | Cardiolipin IgM: | <12.5 MPL U/mL |
| Cardiolipin IgG: | <15 GPL U/mL | | | | | | |
| Cardiolipin IgA: | <12 APL U/mL | | | | | | |
| Cardiolipin IgM: | <12.5 MPL U/mL | | | | | | |
| Clinical Utility: | Elevated levels are seen either transiently in some infectious diseases or more persistently in autoimmune diseases, such as SLE and APS. Anticardiolipin antibodies have also been associated with fetal loss, endocarditis, cardiovascular disease, and hemolytic anemia. Testing is best utilized when performed in parallel with a Beta-2-Glycoprotein-1 Antibody Profile. | | | | | | |

| Test Name | Order Code |
|----------------------------|---|
| CD4/CD8 Profile | CD4PR |
| Alternate Name: | <ul style="list-style-type: none">• CD4/CD8• Helper/Suppressor Ratio• Flow Cytometry |
| Includes: | <ul style="list-style-type: none">• CD45 Total Lymph Count• Absolute and % T cells (CD3)• Absolute and % Helper cells (CD4)• Absolute and % suppressor cells (CD8)• Helper/Suppressor Ratio |
| Suggest CPT coding: | 86359,86360 |
| Methodology: | Flow Cytometry |
| Testing Schedule: | Routine, Monday- Friday no holidays |
| Report Available: | 2-4 days |
| Minimum Volume: | 3 mL whole blood |
| Container: | Lavender top tube, <u>EDTA</u> |

Continued...

| Test Name CD4/CD8 Profile | | Order Code CD4PR |
|--|--|----------------------------|
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Store as whole blood in original tube at room temperature.• The Department of Health requires mandatory reporting of any abnormal CD4 result. | |
| Reference Range: | See Patient Report | |
| Clinical Utility: | Quantitates as a percentage and as an absolute count the CD4 Helper T-lymphocyte population, the CD8 Suppressor T-lymphocyte population, the CD3 total T-lymphocyte population and the total lymphocyte count. | |

| Test Name Chlamydia Antibody Profile | | Order Code CHLAB |
|--|--|----------------------------|
| Includes: | <ul style="list-style-type: none">• Chlamydia pneumoniae IgG and IgM antibodies• Chlamydia psittaci IgG and IgM antibodies• Chlamydia trachomatis IgG and IgM antibodies | |
| Suggest CPT coding: | 86631(x3),86632(x3) | |
| Methodology: | Micro-immunofluorescent Antibody Assay (MIF) | |
| Testing Schedule: | Routine, Monday-Saturday | |
| Report Available: | 5-7 days | |
| Minimum Volume: | 1 mL serum | |
| Container: | Gold top tube, <u>serum separator</u> | |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate | |
| Reference Range: | For each constituent IgG: <1:64 IgM: <1:10 | |
| Clinical Utility: | Useful as an aid in the clinical diagnosis of chlamydial infections. | |

| Test Name CK, Total and MB | | Order Code CKIMB |
|--|---|----------------------------|
| Includes: | <ul style="list-style-type: none">• CK, Total• MCKMB (Mass CK-MB Fraction)• Relative Index | |
| Suggest CPT coding: | 82550,82553 | |
| Methodology: | Multiple-point Rate and Direct Chemiluminescence | |
| Testing Schedule: | Routine daily, STAT testing available | |
| Report Available: | 1 day | |
| Minimum Volume: | 1 mL serum | |
| Container: | Gold top tube, <u>serum separator</u> | |
| Collection: | Collect specimen at onset of symptoms to establish baseline values. | |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• CK-MB usually peaks 15-20 hours after the onset of a myocardial infarction.• Testing must be performed within 4 hours of collection.• If delay in testing, centrifuge, transfer to plastic aliquot tube and refrigerate for up to 48 hours. | |

Continued...

| Test Name | Order Code |
|---|--|
| CK, Total and MB | CKIMB |
| Reference Range: | |
| CK, Total: | Refer to order code CK |
| CK-MB:(Healthy, non-hospitalized): | < 5.0 ng/mL |
| Relative Index: | < 2.5% |
| Clinical Utility: | Used in the evaluation of myocardial infarction. |

| Test Name | Order Code |
|--|---|
| Comprehensive Metabolic Panel, Neonatal | NCPMP |
| Includes: | <ul style="list-style-type: none">• Alanine Aminotransferase (ALT)• Albumin• Alkaline Phosphatase• Aspartate Aminotransferase (AST)• Calcium• Carbon dioxide (CO2)• Bilirubin, Total Neonatal• Chloride• Creatinine• Glucose• Potassium• Protein, Total• Sodium• Urea nitrogen (BUN)• Anion Gap Calculation |
| Suggest CPT coding: | 80053 |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine daily, STAT testing available |
| Report Available: | 1 day |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listings |
| Critical Values: | See individual test listings |
| Clinical Utility: | Used as a general organ/system survey and to establish baseline values. |

| Test Name | Order Code |
|--------------------------------------|--|
| Comprehensive Metabolic Panel | CPMP |
| Includes: | <ul style="list-style-type: none"> • Alanine Aminotransferase (ALT) • Albumin • Alkaline phosphatase • Aspartate Aminotransferase (AST) • Calcium • Carbon dioxide (CO2) • Bilirubin, Total • Chloride • Creatinine • Glucose • Potassium • Protein, Total • Sodium • Urea nitrogen (BUN) • Anion Gap Calculation • Glomerular Filtration Rate Calculation (GFR) |
| Suggest CPT coding: | 80053 |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine daily, STAT testing available |
| Report Available: | 1 day |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listings |
| Critical Values: | See individual test listings |
| Clinical Utility: | Used as a general organ/system survey and to establish baseline values. |

| Test Name | Order Code | | | | |
|--|--|-------|-----------------------|-------|-------------------|
| Coxsackie A Antibody Profile | COXAP | | | | |
| Includes: | Antibodies to each of the following: <ul style="list-style-type: none"> • Coxsackie A2, A4, A7, A9, A10, and A16 | | | | |
| Suggest CPT coding: | 86658(x6) | | | | |
| Methodology: | Complement Fixation | | | | |
| Testing Schedule: | Routine Monday–Friday, no holidays | | | | |
| Report Available: | 3–5 days | | | | |
| Minimum Volume: | 2 mL serum | | | | |
| Container: | Gold top tube, <u>serum separator</u> | | | | |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate | | | | |
| Reference Range: | <1:8 | | | | |
| | Interpretation <table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td style="padding: 2px;">< 1:8</td> <td style="padding: 2px;">Antibody NOT Detected</td> </tr> <tr> <td style="padding: 2px;">≥ 1:8</td> <td style="padding: 2px;">Antibody Detected</td> </tr> </tbody> </table> | < 1:8 | Antibody NOT Detected | ≥ 1:8 | Antibody Detected |
| < 1:8 | Antibody NOT Detected | | | | |
| ≥ 1:8 | Antibody Detected | | | | |

Continued...

| Test Name | Order Code |
|-------------------------------------|--|
| Coxsackie A Antibody Profile | COXAP |
| Clinical Utility: | This profile tests against A-2, 4, 7, 9, 10, and 16 antigens. Although cross reactivity exists among the enteroviruses by complement fixation, most healthy people do not have titers $\geq 1:8$. Therefore, detectable titers, especially those $\geq 1:32$, should be considered a positive identification. Confirmation is made by demonstration of a fourfold change in titers between acute and convalescent sera. Single titers of $\geq 1:32$ are indicative of recent infection. Titers of 1:8 or 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable cross reactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype. |

| Test Name | Order Code | | | | |
|--|--|------|-----------------------|------------|-------------------|
| Coxsackie B Antibody Profile | CXVB | | | | |
| Includes: | Antibodies to each of the following: <ul style="list-style-type: none"> Coxsackie B1, B2, qa B3, B4, B5, and B6 | | | | |
| Suggest CPT coding: | 86658(x6) | | | | |
| Methodology: | Complement Fixation | | | | |
| Testing Schedule: | Routine, Monday–Friday no holidays | | | | |
| Report Available: | 3–5 days | | | | |
| Minimum Volume: | 2 mL serum | | | | |
| Container: | Gold top tube, <u>serum separator</u> | | | | |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. | | | | |
| Reference Range: | < 1:8 Interpretation <table border="1" style="width: 100%;"> <tr> <td><1:8</td> <td>Antibody NOT Detected</td> </tr> <tr> <td>$\geq 1:8$</td> <td>Antibody Detected</td> </tr> </table> | <1:8 | Antibody NOT Detected | $\geq 1:8$ | Antibody Detected |
| <1:8 | Antibody NOT Detected | | | | |
| $\geq 1:8$ | Antibody Detected | | | | |
| Clinical Utility: | This profile includes testing against the 6 immunotypes of Coxsackie B viruses. Although there is cross reactivity among the enteroviruses by complement fixation, most healthy people do not have titers $\geq 1:8$. Therefore detectable titers, especially those $\geq 1:32$, should be considered a positive identification. Confirmation is made by demonstration of a fourfold change in titers between acute and convalescent sera. | | | | |

| Test Name | Order Code |
|---|---|
| Cytomegalovirus Antibody Profile | CMVP |
| Includes: | CMV IgG and IgM antibodies |
| Suggest CPT coding: | 86644,86645 |
| Methodology: | Enzyme–Linked Immunosorbent Assay (ELISA) |
| Testing Schedule: | Routine, 1–2 times per week |
| Report Available: | 4–7 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |

Continued...

| Test Name | | Order Code |
|---|--|-------------------|
| Cytomegalovirus Antibody Profile | | CMVP |
| Reference Range: | See individual test listings. | |
| Clinical Utility: | Supports the serodiagnosis of CMV infection. | |

| Test Name | | Order Code |
|---|---|-------------------|
| Disseminated Intravascular Coagulation Profile | | DIC |
| Includes: | <ul style="list-style-type: none"> Fibrinogen Platelet Count D-Dimer, Quantitative | |
| Suggest CPT coding: | 85379, 85384 (note: Platelet Count CPT 85049 will be charged separately if CBC not included in order) | |
| Methodology: | See individual test listings | |
| Testing Schedule: | Routine daily, STAT testing available | |
| Report Available: | 1 day | |
| Minimum Volume: | 1 mL citrated plasma AND 1 mL EDTA whole blood | |
| Container: | 1 Full Light Blue top tube, <u>sodium citrate</u> AND 1 Lavender top tube, <u>EDTA</u> | |
| Collection: | See Special handling instructions for "Coagulation Studies", listed under Specimen Collection, Preparation, and Handling Section | |
| Reference Range: | See Individual Test Listings | |
| Critical Values: | See Individual Test Listings | |
| Clinical Utility: | Used in the evaluation of DIC, including abnormalities in platelet count, fibrinogen, fibrin split products, and fibrinolytic activity. | |

| Test Name | | Order Code | | | | | | | | | | | | |
|---|---|-------------------|-------|----------------------|--------------|-----------|--------------|----------|---------|-----------|---------|------------|---------------|----------|
| Drug Screen 5, Urine with Confirmation, Forensic | | IM5 | | | | | | | | | | | | |
| Includes: | <p>Screen for the following classes of drugs:</p> <table border="1"> <thead> <tr> <th>Class</th> <th>Cutoff Concentration</th> </tr> </thead> <tbody> <tr> <td>Amphetamines</td> <td>500 ng/mL</td> </tr> <tr> <td>Cannabinoids</td> <td>50 ng/mL</td> </tr> <tr> <td>Cocaine</td> <td>150 ng/mL</td> </tr> <tr> <td>Opiates</td> <td>2000 ng/mL</td> </tr> <tr> <td>Phencyclidine</td> <td>25 ng/mL</td> </tr> </tbody> </table> <p>Testing also includes specimen validity tests to check for specimen integrity and adulteration. Confirmation of positive screen results by Gas Chromatography–Mass Spectrometry (GC/MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC/MS/MS) .</p> | | Class | Cutoff Concentration | Amphetamines | 500 ng/mL | Cannabinoids | 50 ng/mL | Cocaine | 150 ng/mL | Opiates | 2000 ng/mL | Phencyclidine | 25 ng/mL |
| Class | Cutoff Concentration | | | | | | | | | | | | | |
| Amphetamines | 500 ng/mL | | | | | | | | | | | | | |
| Cannabinoids | 50 ng/mL | | | | | | | | | | | | | |
| Cocaine | 150 ng/mL | | | | | | | | | | | | | |
| Opiates | 2000 ng/mL | | | | | | | | | | | | | |
| Phencyclidine | 25 ng/mL | | | | | | | | | | | | | |
| Suggest CPT coding: | 80101(X5) | | | | | | | | | | | | | |
| Methodology: | Immunoassay (IA) | | | | | | | | | | | | | |
| Testing Schedule: | Routine, Monday–Friday | | | | | | | | | | | | | |
| Report Available: | 1–3 business days | | | | | | | | | | | | | |
| Minimum Volume: | 10 mL urine | | | | | | | | | | | | | |
| Container: | Plastic urine container with temperature strip | | | | | | | | | | | | | |
| Collection: | <ul style="list-style-type: none"> Use protocol for collection of forensic specimens to include Chain-of-Custody Form. Submit sealed urine with a Chain-of-Custody (HNL– 53) Form in a sealed evidence bag. | | | | | | | | | | | | | |

Continued...

| Test Name | | Order Code |
|---|--|-------------------|
| Drug Screen 5, Urine with Confirmation, Forensic | | IM5 |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Forensic collection protocol must be followed.• Drug Testing Request/Chain-of-Custody Form must be submitted with specimen.• This test is intended for Forensic and Employment related drug testing. | |
| Reference Range: | Negative | |
| Clinical Utility: | Useful for detecting drug abuse. | |

| Test Name | | Order Code | | | | | | | | | | | | |
|--|---|-------------------|----------------------|--------------|-----------|--------------|----------|---------|-----------|---------|-----------|---------------|----------|--|
| Drug Screen 5, Urine without Confirmation | | DOA5 | | | | | | | | | | | | |
| Includes: | <u>Screen for the following classes of drugs:</u> | | | | | | | | | | | | | |
| | <table border="1"><thead><tr><th>Class</th><th>Cutoff Concentration</th></tr></thead><tbody><tr><td>Amphetamines</td><td>500 ng/mL</td></tr><tr><td>Cannabinoids</td><td>50 ng/mL</td></tr><tr><td>Cocaine</td><td>150 ng/mL</td></tr><tr><td>Opiates</td><td>300 ng/mL</td></tr><tr><td>Phencyclidine</td><td>25 ng/mL</td></tr></tbody></table> | Class | Cutoff Concentration | Amphetamines | 500 ng/mL | Cannabinoids | 50 ng/mL | Cocaine | 150 ng/mL | Opiates | 300 ng/mL | Phencyclidine | 25 ng/mL | |
| Class | Cutoff Concentration | | | | | | | | | | | | | |
| Amphetamines | 500 ng/mL | | | | | | | | | | | | | |
| Cannabinoids | 50 ng/mL | | | | | | | | | | | | | |
| Cocaine | 150 ng/mL | | | | | | | | | | | | | |
| Opiates | 300 ng/mL | | | | | | | | | | | | | |
| Phencyclidine | 25 ng/mL | | | | | | | | | | | | | |
| | NOTE: This is a Presumptive test. Confirmation testing is not performed. | | | | | | | | | | | | | |
| Suggest CPT coding: | 80101(x4),80101 | | | | | | | | | | | | | |
| Methodology: | Immunoassay (IA) | | | | | | | | | | | | | |
| Testing Schedule: | Routine, daily | | | | | | | | | | | | | |
| Report Available: | 1 day | | | | | | | | | | | | | |
| Minimum Volume: | 5 mL urine | | | | | | | | | | | | | |
| Container: | Plastic urine container | | | | | | | | | | | | | |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Chain-of-Custody Form optional• This is a presumptive test and not intended for employment-related testing.• Confirmation testing may be requested/added up to 2 weeks after reporting of initial results.• NOTE: Positive samples are only retained for 2 weeks. | | | | | | | | | | | | | |
| Reference Range: | Negative | | | | | | | | | | | | | |
| Clinical Utility: | Useful for detecting drug abuse. | | | | | | | | | | | | | |

| Test Name | | Order Code | | | | | | | | | | | | | | | | |
|---|--|-------------------|----------------------|--------------|-----------|--------------|-----------|-----------------|-----------|--------------|----------|---------|-----------|---------|-----------|---------------|----------|--|
| Drug Screen 7, Urine with Confirmation, Forensic | | IM7 | | | | | | | | | | | | | | | | |
| Includes: | <u>Screen for the following classes of drugs:</u> | | | | | | | | | | | | | | | | | |
| | <table border="1"><thead><tr><th>Class</th><th>Cutoff Concentration</th></tr></thead><tbody><tr><td>Amphetamines</td><td>500 ng/ml</td></tr><tr><td>Barbiturates</td><td>200 ng/ml</td></tr><tr><td>Benzodiazepines</td><td>200 ng/ml</td></tr><tr><td>Cannabinoids</td><td>50 ng/ml</td></tr><tr><td>Cocaine</td><td>150 ng/ml</td></tr><tr><td>Opiates</td><td>300 ng/ml</td></tr><tr><td>Phencyclidine</td><td>25 ng/ml</td></tr></tbody></table> | Class | Cutoff Concentration | Amphetamines | 500 ng/ml | Barbiturates | 200 ng/ml | Benzodiazepines | 200 ng/ml | Cannabinoids | 50 ng/ml | Cocaine | 150 ng/ml | Opiates | 300 ng/ml | Phencyclidine | 25 ng/ml | |
| Class | Cutoff Concentration | | | | | | | | | | | | | | | | | |
| Amphetamines | 500 ng/ml | | | | | | | | | | | | | | | | | |
| Barbiturates | 200 ng/ml | | | | | | | | | | | | | | | | | |
| Benzodiazepines | 200 ng/ml | | | | | | | | | | | | | | | | | |
| Cannabinoids | 50 ng/ml | | | | | | | | | | | | | | | | | |
| Cocaine | 150 ng/ml | | | | | | | | | | | | | | | | | |
| Opiates | 300 ng/ml | | | | | | | | | | | | | | | | | |
| Phencyclidine | 25 ng/ml | | | | | | | | | | | | | | | | | |
| | Testing also includes specimen validity tests to check for specimen integrity and adulteration. Confirmation of positive screen results by Gas Chromatography–Mass Spectrometry (GC/MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC/MS/MS) . | | | | | | | | | | | | | | | | | |

Continued...

| Test Name | | Order Code |
|---|--|-------------------|
| Drug Screen 7, Urine with Confirmation, Forensic | | IM7 |
| Suggest CPT coding: | 80101(x7) | |
| Methodology: | Immunoassay (IA) | |
| Testing Schedule: | Routine, Monday–Friday | |
| Report Available: | 3–5 days | |
| Minimum Volume: | 10 mL urine | |
| Container: | Plastic urine container with temperature strip | |
| Collection: | <ul style="list-style-type: none">• Use protocol for collection of forensic specimens to include Chain-of-Custody Form.• Seal urine with evidence tape and place with Chain-of-Custody Form in a sealed evidence bag. | |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Chain-of-Custody procedures must be followed to ensure specimen integrity.• Submit specimen with a completed Drug Testing Request/Chain-of-Custody (HNL-53) Form.• This test is intended for Forensic and Employment related drug testing. | |
| Reference Range: | Negative | |
| Clinical Utility: | Useful for detecting drug abuse. | |

| Test Name | | Order Code | | | | | | | | | | | | | | | | |
|--|--|-------------------|----------------------|--------------|-----------|--------------|-----------|-----------------|-----------|--------------|----------|---------|-----------|---------|-----------|---------------|----------|--|
| Drug Screen 7, Urine without Confirmation | | DOA7 | | | | | | | | | | | | | | | | |
| Includes: | <u>Screen for the following classes of drugs:</u> | | | | | | | | | | | | | | | | | |
| | <table border="1"><thead><tr><th>Class</th><th>Cutoff Concentration</th></tr></thead><tbody><tr><td>Amphetamines</td><td>500 ng/mL</td></tr><tr><td>Barbiturates</td><td>200 ng/mL</td></tr><tr><td>Benzodiazepines</td><td>200 ng/mL</td></tr><tr><td>Cannabinoids</td><td>50 ng/mL</td></tr><tr><td>Cocaine</td><td>150 ng/mL</td></tr><tr><td>Opiates</td><td>300 ng/mL</td></tr><tr><td>Phencyclidine</td><td>25 ng/mL</td></tr></tbody></table> | Class | Cutoff Concentration | Amphetamines | 500 ng/mL | Barbiturates | 200 ng/mL | Benzodiazepines | 200 ng/mL | Cannabinoids | 50 ng/mL | Cocaine | 150 ng/mL | Opiates | 300 ng/mL | Phencyclidine | 25 ng/mL | |
| Class | Cutoff Concentration | | | | | | | | | | | | | | | | | |
| Amphetamines | 500 ng/mL | | | | | | | | | | | | | | | | | |
| Barbiturates | 200 ng/mL | | | | | | | | | | | | | | | | | |
| Benzodiazepines | 200 ng/mL | | | | | | | | | | | | | | | | | |
| Cannabinoids | 50 ng/mL | | | | | | | | | | | | | | | | | |
| Cocaine | 150 ng/mL | | | | | | | | | | | | | | | | | |
| Opiates | 300 ng/mL | | | | | | | | | | | | | | | | | |
| Phencyclidine | 25 ng/mL | | | | | | | | | | | | | | | | | |
| | NOTE: Presumptive positive only. Confirmation testing is not performed. | | | | | | | | | | | | | | | | | |
| Suggest CPT coding: | 80101(x7) | | | | | | | | | | | | | | | | | |
| Methodology: | Immunoassay (IA) | | | | | | | | | | | | | | | | | |
| Testing Schedule: | Routine, daily | | | | | | | | | | | | | | | | | |
| Report Available: | 1 day | | | | | | | | | | | | | | | | | |
| Minimum Volume: | 2 mL urine | | | | | | | | | | | | | | | | | |
| Container: | Plastic urine container or tube | | | | | | | | | | | | | | | | | |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Chain-of-Custody Form optional• This is a presumptive test and not intended for employment-related testing.• Confirmation testing may be requested/added up to 2 weeks after reporting of initial results.• NOTE: Positive samples are only retained for 2 weeks. | | | | | | | | | | | | | | | | | |
| Reference Range: | Negative | | | | | | | | | | | | | | | | | |
| Clinical Utility: | Useful for detecting drug abuse. | | | | | | | | | | | | | | | | | |

| Test Name | | Order Code | | | | | | | | | | | | | | | | | | | | |
|---|---|-------------------|-------|----------------------|--------------|-----------|--------------|-----------|-----------------|-----------|--------------|----------|---------|-----------|-----------|-----------|---------|------------|---------------|----------|--------------|-----------|
| Drug Screen 9, Urine with Confirmation, Forensic | | IMDS | | | | | | | | | | | | | | | | | | | | |
| Includes: | <u>Screen for the following classes of drugs:</u> | | | | | | | | | | | | | | | | | | | | | |
| | <table border="1"> <thead> <tr> <th>Class</th> <th>Cutoff Concentration</th> </tr> </thead> <tbody> <tr> <td>Amphetamines</td> <td>500 ng/mL</td> </tr> <tr> <td>Barbiturates</td> <td>200 ng/mL</td> </tr> <tr> <td>Benzodiazepines</td> <td>200 ng/mL</td> </tr> <tr> <td>Cannabinoids</td> <td>50 ng/mL</td> </tr> <tr> <td>Cocaine</td> <td>150 ng/mL</td> </tr> <tr> <td>Methadone</td> <td>300 ng/mL</td> </tr> <tr> <td>Opiates</td> <td>2000 ng/mL</td> </tr> <tr> <td>Phencyclidine</td> <td>25 ng/mL</td> </tr> <tr> <td>Propoxyphene</td> <td>300 ng/mL</td> </tr> </tbody> </table> | | Class | Cutoff Concentration | Amphetamines | 500 ng/mL | Barbiturates | 200 ng/mL | Benzodiazepines | 200 ng/mL | Cannabinoids | 50 ng/mL | Cocaine | 150 ng/mL | Methadone | 300 ng/mL | Opiates | 2000 ng/mL | Phencyclidine | 25 ng/mL | Propoxyphene | 300 ng/mL |
| Class | Cutoff Concentration | | | | | | | | | | | | | | | | | | | | | |
| Amphetamines | 500 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Barbiturates | 200 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Benzodiazepines | 200 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Cannabinoids | 50 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Cocaine | 150 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Methadone | 300 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Opiates | 2000 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Phencyclidine | 25 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Propoxyphene | 300 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| | <p>Testing also includes specimen validity tests to check for specimen integrity and adulteration. Confirmation of positive screen results by Gas Chromatography–Mass Spectrometry (GC/MS) or Liquid Chromatography–Tandem Mass Spectrometry (LC/MS/MS).</p> | | | | | | | | | | | | | | | | | | | | | |
| Suggest CPT coding: | (80101x9) | | | | | | | | | | | | | | | | | | | | | |
| Methodology: | Immunoassay (IA) | | | | | | | | | | | | | | | | | | | | | |
| Testing Schedule: | Routine, Monday–Friday | | | | | | | | | | | | | | | | | | | | | |
| Report Available: | 1–3 business days | | | | | | | | | | | | | | | | | | | | | |
| Minimum Volume: | 10 mL urine | | | | | | | | | | | | | | | | | | | | | |
| Container: | Plastic urine container with temperature strip | | | | | | | | | | | | | | | | | | | | | |
| Collection: | <ul style="list-style-type: none"> • Use protocol for collection of forensic specimens to include Chain-of-Custody Form. • Seal urine with evidence tape and place with Chain-of-Custody Form in a sealed evidence bag. | | | | | | | | | | | | | | | | | | | | | |
| Special Instructions and/or Comments: | <ul style="list-style-type: none"> • Chain-of-Custody procedures must be followed to ensure specimen integrity. • Submit specimen with a completed Drug Testing Request/Chain-of-Custody (HNL-53) Form. • This test is intended for forensic and employment-related drug testing. | | | | | | | | | | | | | | | | | | | | | |
| Reference Range: | Negative | | | | | | | | | | | | | | | | | | | | | |
| Clinical Utility: | Useful for detecting drug abuse. | | | | | | | | | | | | | | | | | | | | | |

| Test Name | | Order Code | | | | | | | | | | | | | | | | | | | | |
|--|--|-------------------|-------|----------------------|--------------|-----------|--------------|-----------|-----------------|-----------|--------------|----------|---------|-----------|-----------|-----------|---------|-----------|---------------|----------|--------------|-----------|
| Drug Screen 9, Urine without Confirmation | | DOA9 | | | | | | | | | | | | | | | | | | | | |
| Includes: | <u>Screen for the following classes of drugs:</u> | | | | | | | | | | | | | | | | | | | | | |
| | <table border="1"> <thead> <tr> <th>Class</th> <th>Cutoff Concentration</th> </tr> </thead> <tbody> <tr> <td>Amphetamines</td> <td>500 ng/mL</td> </tr> <tr> <td>Barbiturates</td> <td>200 ng/mL</td> </tr> <tr> <td>Benzodiazepines</td> <td>200 ng/mL</td> </tr> <tr> <td>Cannabinoids</td> <td>50 ng/mL</td> </tr> <tr> <td>Cocaine</td> <td>150 ng/mL</td> </tr> <tr> <td>Methadone</td> <td>300 ng/mL</td> </tr> <tr> <td>Opiates</td> <td>300 ng/mL</td> </tr> <tr> <td>Phencyclidine</td> <td>25 ng/mL</td> </tr> <tr> <td>Propoxyphene</td> <td>300 ng/mL</td> </tr> </tbody> </table> | | Class | Cutoff Concentration | Amphetamines | 500 ng/mL | Barbiturates | 200 ng/mL | Benzodiazepines | 200 ng/mL | Cannabinoids | 50 ng/mL | Cocaine | 150 ng/mL | Methadone | 300 ng/mL | Opiates | 300 ng/mL | Phencyclidine | 25 ng/mL | Propoxyphene | 300 ng/mL |
| Class | Cutoff Concentration | | | | | | | | | | | | | | | | | | | | | |
| Amphetamines | 500 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Barbiturates | 200 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Benzodiazepines | 200 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Cannabinoids | 50 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Cocaine | 150 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Methadone | 300 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Opiates | 300 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Phencyclidine | 25 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| Propoxyphene | 300 ng/mL | | | | | | | | | | | | | | | | | | | | | |
| | <p>NOTE: Presumptive positive only. Confirmation testing is not performed.</p> | | | | | | | | | | | | | | | | | | | | | |
| Suggest CPT coding: | 80101(x9) | | | | | | | | | | | | | | | | | | | | | |

Continued...

| Test Name | Order Code |
|--|---|
| Drug Screen 9, Urine without Confirmation | DOA9 |
| Methodology: | Immunoassay (IA) |
| Testing Schedule: | Routine, daily |
| Report Available: | 1 day |
| Minimum Volume: | 2 mL urine |
| Container: | Plastic urine container |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Chain-of-Custody Form optional• This is a presumptive test and not intended for employment-related testing.• Confirmation testing may be requested/added up to 2 weeks after reporting of initial results.• NOTE: Positive samples are only retained for 2 weeks. |
| Reference Range: | Negative |
| Clinical Utility: | Useful for detecting drug abuse. |

| Test Name | Order Code |
|--|--|
| ECHO virus Antibody Profile | ECHAP |
| Includes: | Antibodies to each of the following: ECHO virus 4, 7, 9, 11, and 30 |
| Suggest CPT coding: | 86658(x5) |
| Methodology: | Complement Fixation |
| Testing Schedule: | Routine, Monday-Friday no holidays |
| Report Available: | 2-4 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. |
| Reference Range: | <1:8 NOTE: Compare acute and convalescent titers for greatest diagnostic value. A fourfold or greater increase in titer between acute and convalescent specimens confirms the diagnosis of recent infection. |
| Clinical Utility: | Single titers \geq 1:32 are indicative of recent infection. Titers of 1:8 or 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype. |

| Test Name | Order Code |
|-----------------------------------|---|
| Ehrlichia Antibody Profile | EHCP |
| Alternate Name: | Ehrlichia chaffeensis (HME) and Anaplasma phagocytophilia (HGE) IgG and IgM antibodies |
| Includes: | IgG and IgM Antibodies to each of the following: <ul style="list-style-type: none">• Ehrlichia chaffeensis (HME)• Anaplasma phagocytophilia (previously known as Ehrlichia equi) (HGE) |
| Suggest CPT coding: | 86666(x4) |
| Methodology: | Indirect Fluorescent Antibody (IFA) |
| Testing Schedule: | Routine, 2 times per week |
| Report Available: | 3-5 days |
| Minimum Volume: | 1 mL serum |

Continued...

| Test Name | | Order Code | | | | | | | | | | |
|--|--|-------------------|------------------------------------|--|-------------------|-------|--|--|------|-------|------|-------|
| Ehrlichia Antibody Profile | | EHCP | | | | | | | | | | |
| Container: | Gold top tube, <u>serum separator</u> | | | | | | | | | | | |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. | | | | | | | | | | | |
| Reference Range: | <table border="1"> <tbody> <tr> <td colspan="2">Ehrlichia chaffeensis (HME)</td> </tr> <tr> <td>Both IgG and IgM:</td> <td><1:40</td> </tr> <tr> <td colspan="2">Anaplasma phagocytophilia (HGE)</td> </tr> <tr> <td>IgG:</td> <td><1:80</td> </tr> <tr> <td>IgM:</td> <td><1:20</td> </tr> </tbody> </table> | | Ehrlichia chaffeensis (HME) | | Both IgG and IgM: | <1:40 | Anaplasma phagocytophilia (HGE) | | IgG: | <1:80 | IgM: | <1:20 |
| Ehrlichia chaffeensis (HME) | | | | | | | | | | | | |
| Both IgG and IgM: | <1:40 | | | | | | | | | | | |
| Anaplasma phagocytophilia (HGE) | | | | | | | | | | | | |
| IgG: | <1:80 | | | | | | | | | | | |
| IgM: | <1:20 | | | | | | | | | | | |
| Clinical Utility: | Detectable IgM levels generally rise 3 to 5 days post infection or 24 hours after the initial onset of fever, falling again to undetectable levels in about 30 to 60 days. IgG levels often are detectable 7 to 10 days post-infection, peaking at about 14 to 21 days and persisting for approximately 1 year | | | | | | | | | | | |

| Test Name | | Order Code |
|----------------------------|--|-------------------|
| Electrolytes, Serum | | ELEC |
| Alternate Name: | <ul style="list-style-type: none"> • Lytes, Blood • Plasma Electrolytes • Serum Electrolytes | |
| Includes: | <ul style="list-style-type: none"> • Sodium • Potassium • Chloride • Carbon dioxide (CO2) • Anion Gap Calculation | |
| Suggest CPT coding: | 80051 | |
| Methodology: | See individual test listings | |
| Testing Schedule: | Routine daily, STAT testing available | |
| Report Available: | 1 day | |
| Minimum Volume: | 1 mL serum | |
| Container: | Gold top tube, <u>serum separator</u> | |
| Reference Range: | See individual test listings | |
| Critical Values: | See individual test listings | |
| Clinical Utility: | Used to evaluate electrolyte and acid/base balance. | |

| Test Name | | Order Code |
|-------------------------------------|---|-------------------|
| Enterovirus Antibody Profile | | ENTAP |
| Includes: | Antibodies to each of the following: <ul style="list-style-type: none"> • Coxsackie A Virus: A2, A4, A7, A9, A10, A16 • Coxsackie B Virus: B1, B2, B3, B4, B5, B6 • ECHO Virus: 4, 7, 9, 11, 30 • Poliovirus: 1, 2, and 3 | |
| Suggest CPT coding: | 86658(x20) | |
| Methodology: | Complement Fixation | |
| Testing Schedule: | Routine, 1 time per week | |

Continued...

| Test Name | Order Code |
|--|--|
| Enterovirus Antibody Profile | ENTAP |
| Report Available: | 7–10 days |
| Minimum Volume: | 3 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Special Instructions and/or Comments: | Centrifuge specimens, transfer serum to aliquot tube and refrigerate. |
| Reference Range: | <1:8 NOTE: Compare acute and convalescent titers for greatest diagnostic value. A fourfold or greater increase in titer between acute and convalescent specimens confirms the diagnosis of recent infection. |
| Clinical Utility: | Single titers \geq 1:32 are indicative of recent infection. Titers of 1:8 and 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. There is considerable cross reactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype. |

| Test Name | Order Code |
|--|---|
| Epstein Barr Virus Antibody Profile | EBVP |
| Alternate Name: | <ul style="list-style-type: none">• EBV Antibody• EBV Antibody Panel• EBV IgG/IgM• EBV Serology• EBV Titers |
| Includes: | <ul style="list-style-type: none">• VCA IgG Antibody• VCA IgM Antibody• Antibody to Early Antigen• Antibody to EBNA• Interpretation |
| Suggest CPT coding: | 86663,86664,86665(x2) |
| Methodology: | Enzyme-Linked Immunosorbent Assay (ELISA) |
| Testing Schedule: | Routine, 2 times per week |
| Report Available: | 3–7 days |
| Minimum Volume: | 2 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | \leq 0.90 |
| Clinical Utility: | Primary EBV infection is shown with IgM-VCA appearing first, accompanied by rising IgG-VCA antibody levels and the appearance of antibody to Early Antigen. If both IgG-VCA and EBNA antibodies are present, past infection is indicated. |

| Test Name | Order Code |
|-----------------------------------|---|
| Heparin Resistance Profile | HPRP |
| Includes: | <ul style="list-style-type: none">• Antithrombin III Activity• Factor VIII Activity• Fibrinogen• Heparin Level, Unfractionated• Partial Thromboplastin Time, Activated (APTT) |
| Suggest CPT coding: | 85240,85300,85384,85520,85730 |

Continued...

| Test Name | Order Code |
|--|--|
| Heparin Resistance Profile | HPRP |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine, 1 time per week |
| Report Available: | 5–7 days (individual components resulted as performed) |
| Minimum Volume: | 2 mL prepared “platelet poor plasma” split equally into 4 plastic aliquot tubes and FROZEN immediately |
| Container: | 4 Full Light Blue top tubes, <u>sodium citrate</u> |
| Collection: | See Special Handling Instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Testing is contraindicated for patients on Heparin or Coumadin therapy.• Preparation and submission of “platelet poor plasma” is critical for accurate test performance and interpretation. |
| Reference Range: | See individual test listings. |
| Critical Values: | See order codes FIBR, HEPL and PTT |

| Test Name | Order Code |
|--|--|
| Hepatitis B Profile | HBP |
| Includes: | <ul style="list-style-type: none">• Hepatitis B Surface Antigen (HbsAg)• Hepatitis B Surface Antibody (HbsAb)• Hepatitis B Core Antibody, Total (HbcAb, Total)• Hepatitis B Core Antibody, IgM (HbcAb, IgM)• Interpretation of results• Reflexed when appropriate: Hepatitis B Surface Antigen Neutralization |
| Suggest CPT coding: | 86704,86705,86706,87340 |
| Methodology: | Chemiluminescent Microparticle Enzyme Immunoassay (CMIA) |
| Testing Schedule: | Routine, 6 times per week |
| Report Available: | 1–3 days |
| Minimum Volume: | 3 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Special Instructions and/or Comments: | The Department of Health requires mandatory reporting of a confirmed positive HBsAg or a positive HbcAb IgM result. |
| Reference Range: | See individual test listings |
| Clinical Utility: | Differential diagnosis of Hepatitis and stage Hepatitis B infection. IgM antibody to Hepatitis B core antigen is a reliable marker for acute Hepatitis B viral infection. Presence of Hepatitis B surface antibody is an indicator of clinical recovery and subsequent immunity to Hepatitis B virus. This test is useful for evaluation of possible immunity in individuals who are at increased risk for exposure to Hepatitis B, i.e., hemodialysis unit personnel, venipuncturists, etc. Evaluation of the need for hepatitis B immune globulin after needlestick injury. Evaluation of the need for Hepatitis B vaccine, and to follow immune status after hepatitis B vaccine. Hepatitis B surface antigen is the earliest indicator of the presence of acute infection and is also indicative of chronic infection. |

| Test Name | Order Code |
|--|---|
| Hepatitis C Antibody Profile | HCP |
| Includes: | <ul style="list-style-type: none"> Hepatitis C (HCV) Antibody Screen Reflexed when appropriate: HCV PCR |
| Suggest CPT coding: | 86803 |
| Methodology: | Chemiluminescent Microparticle Enzyme Immunoassay (CMIA) and RNA Quantitation by PCR |
| Testing Schedule: | Routine, 5 times per week |
| Report Available: | 2–4 days |
| Minimum Volume: | 4 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Special Instructions and/or Comments: | The Department of Health requires mandatory reporting of any confirmed positive result. |
| Reference Range: | Negative: No antibody detected. |
| Clinical Utility: | Assess exposure to hepatitis C virus. HCV antibodies are typically not detected until approximately 14 weeks after exposure (or 5 weeks after appearance of the first biochemical marker of illness); absence of these antibodies after this period is strong evidence against HCV infection. |

| Test Name | Order Code |
|-------------------------------|--|
| Hepatitis Panel, Acute | AHEP |
| Includes: | <ul style="list-style-type: none"> Hepatitis A Antibody, IgM (HAV Ab, IgM) Hepatitis B Surface Antigen (HbsAg) Hepatitis B Core Antibody, IgM (HbcAb, IgM) Hepatitis C (HCV) Antibody Screen Interpretation of results Reflexed when appropriate: Hepatitis B Surface Antigen Neutralization HCV PCR |
| Suggest CPT coding: | 80074 |
| Methodology: | Chemiluminescent Microparticle Enzyme Immunoassay (CMIA) |
| Testing Schedule: | Routine, 6 times per week |
| Report Available: | 3–7 days |
| Minimum Volume: | 3 mL serum |
| Container: | 2 Gold top tubes, <u>serum separator</u> |
| Reference Range: | See individual test listings. |
| Clinical Utility: | Comprehensive assessment of suspected hepatitis A and B and C infection in at-risk patients. |

| Test Name | Order Code |
|--|--|
| Herpes Simplex Virus IgG Antibody Profile | HSVGP |
| Includes: | HSV-1 and HSV-2 IgG type specific antibodies |
| Suggest CPT coding: | 86695,86696 |
| Methodology: | Enzyme-Linked Immunosorbent Assay (ELISA) |
| Testing Schedule: | Routine, 1–2 times per week |
| Report Available: | 4–7 days |
| Minimum Volume: | 1 mL serum |

Continued...

| Test Name | Order Code |
|--|--|
| Herpes Simplex Virus IgG Antibody Profile | HSVGP |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | ≤ 0.90 Ab index |
| Clinical Utility: | Herpes Simplex produces several different conditions in man, most often occurring at the oral mucocutaneous junction with the formation of cold sores. This test code provides differentiation of Type 1 or Type 2 Herpes. |

| Test Name | Order Code |
|--|--|
| Herpes Simplex Virus IgM Antibody Profile | HSVMB |
| Includes: | HSV-1 and HSV-2 IgM antibodies |
| Suggest CPT coding: | 86695,86696 |
| Methodology: | Indirect Immunofluorescent Assay (IFA) |
| Testing Schedule: | Routine, 1 time per week |
| Report Available: | 4-7 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | Negative NOTE: Unlike the HSV IgG 1 and 2 type specific assays, the HSV 1 and 2 IgM assays are not type specific and cross-reactivity may occur. |
| Clinical Utility: | Herpes Simplex produces several different conditions in man, most often occurring at the oral mucocutaneous junction with the formation of cold sores. |

| Test Name | Order Code |
|--|---|
| HIV-1 and 2 Antibody Profile | HIV12 |
| Includes: | <ul style="list-style-type: none">• HIV-1 and 2 Antibody Screen• Reflexed when appropriate to Western Blot (Order code: WBHIV) |
| Suggest CPT coding: | 86703 |
| Methodology: | HIV-1 and 2 Antibody Screen: Enzyme Immunoassay (EIA) Reflex Confirmation:Western Blot (WB) |
| Testing Schedule: | Routine, daily |
| Report Available: | 2-4 days (may be extended if Western Blot required) |
| Minimum Volume: | 2 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Specimen must be received in the original Vacutainer tube. Aliquot tubes will not be accepted.• The laboratory assumes that appropriate consent and pretest counseling have been performed by the physician prior to the request for testing.Consent forms should remain on the patient's chart, DO NOT send to the laboratory.• The Department of Health requires mandatory reporting of any confirmed positive result.• Repeatedly reactive screens will automatically be confirmed by Western Blot.These are preliminary until Western Blot results are available and final interpretation is made. |
| Reference Range: | Negative: No antibody detected. |

Continued...

| Test Name | | Order Code |
|-------------------------------------|--|-------------------|
| HIV-1 and 2 Antibody Profile | | HIV12 |
| Clinical Utility: | HIV-1 is the causative agent of AIDS (acquired immune deficiency syndrome) in humans. The HIV virus infects T-lymphocytes, resulting in immune deficiencies, manifested in such diseases as Kaposi's sarcoma, pneumonia, and various infections. HIV-2 is a comparable T-lymphocytic retrovirus that is less virulent, but is becoming more widespread worldwide. HIV-2 is more common outside of the United States, but cases have been reported in the U.S. This test code provides an initial combo enzyme immunoassay screening test for HIV-1 and HIV-2, reflexing to HIV-1 western blot. | |

| Test Name | | Order Code |
|--|--|-------------------|
| HTLV I/II Virus Antibody Profile | | HT12P |
| Includes: | <ul style="list-style-type: none">• HTLV I/II Antibody Screen• Reflexed when appropriate: HTLV I/II Antibody, Western Blot. | |
| Suggest CPT coding: | 86790 | |
| Methodology: | HTLV I/II Antibody Screen: Chemiluminescence, Immunoassay: Reflex Confirmation Western Blot Immunoassay | |
| Testing Schedule: | Routine, 2 times per week | |
| Report Available: | 2-4 days | |
| Minimum Volume: | 1 mL serum | |
| Container: | Gold top tube, <u>serum separator</u> | |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. | |
| Reference Range: | Nonreactive | |
| Clinical Utility: | Useful for laboratory evaluation of patients with proven or suspected ATL or HAM/TSP. Screening of blood, bone marrow, and solid organ donors for asymptomatic infection with HTLV-1 or HTLV-II. | |

| Test Name | | Order Code |
|---------------------------------|---|-------------------|
| Immunoglobulin Profile 1 | | IGAM |
| Includes: | <ul style="list-style-type: none">• IgG• IgA• IgM | |
| Suggest CPT coding: | 82784(x3) | |
| Methodology: | Rate Nephelometry | |
| Testing Schedule: | Routine, 6 times per week | |
| Report Available: | 1-3 days | |
| Minimum Volume: | 1 mL serum | |
| Container: | Gold top tube, <u>serum separator</u> | |
| Reference Range: | See individual test listings. | |
| Clinical Utility: | See individual test listings. | |

| Test Name | Order Code |
|---------------------------------|--|
| Immunoglobulin Profile 2 | IGAME |
| Includes: | <ul style="list-style-type: none"> • IgG • IgA • IgM • IgE |
| Suggest CPT coding: | 82784(x3),82785 |
| Methodology: | Rate nephelometry |
| Testing Schedule: | Routine, 6 times per week |
| Report Available: | 1–3 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listings. |
| Clinical Utility: | See individual test listings. |

| Test Name | Order Code |
|--|--|
| Kidney Stone Diagnostic Risk Profile | KSP |
| Includes: | <ul style="list-style-type: none"> • Volume Measurement • Collection Period • Calcium, Urine • Chloride, Urine • Citrate Excretion, Urine • Creatinine, Urine • Oxalate, Urine • pH, Urine • Phosphorus, Urine • Potassium, Urine • Sodium, Urine • Uric Acid, Urine |
| Suggest CPT coding: | 81002,82340,82436,82507,83945,84105,84133,84300,84560 |
| Methodology: | See individual test listings. |
| Testing Schedule: | Routine, daily |
| Report Available: | 5–7 days |
| Minimum Volume: | Entire 24 hour collection . |
| Container: | 24–Hour plastic urine container, no preservative |
| Collection: | See Special instructions for “24–Hour Urine Collection”, listed under the Specimen Collection, Preparation, and Handling Section. |
| Special Instructions and/or Comments: | Patient should maintain a normal diet prior to testing. |
| Reference Range: | See Individual test listings |
| Clinical Utility: | Utilized to assess the risk of kidney stone development. |

| Test Name | Order Code |
|--|--|
| Legionella pneumophila Antibody Profile | LEGAB |
| Includes: | <ul style="list-style-type: none"> • IgG antibodies to Legionella pneumophila serogroups 1–6 • IgM antibodies to Legionella pneumophila serogroups 1–6 |

Continued...

| Test Name | Order Code |
|--|--|
| Legionella pneumophila Antibody Profile | LEGAB |
| Suggest CPT coding: | 86713(x12) |
| Methodology: | Indirect Fluorescent Antibody (IFA) |
| Testing Schedule: | Routine, 2 times per week |
| Report Available: | 5–7 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | Centrifuge specimen, aliquot serum to plastic aliquot tube and refrigerate |
| Reference Range: | < 1:64 for both IgG and IgM |
| Clinical Utility: | Detect antibodies to Legionella; helps support the clinical diagnosis of Legionnaires' disease |

| Test Name | Order Code |
|---|---|
| Leukemia/Lymphoma Profile, Blood/Bone Marrow, Flow Cytometry | LEUPR |
| Includes: | Flow Cytometry markers appropriate for the clinical presentation. |
| Suggest CPT coding: | 88184,88185(x25) |
| Methodology: | Flow Cytometry |
| Testing Schedule: | Routine, Monday–Friday no holidays |
| Report Available: | 2–4 days |
| Minimum Volume: | 15 mL whole blood OR 5 mL bone marrow |
| Container: | Green top tube, <u>sodium heparin</u> AND Lavender top tube, <u>EDTA</u> |
| Collection: | <ul style="list-style-type: none">• Collect Monday–Friday ONLY before 1400, no holidays.• For special requests contact our Customer Care Department at 610–402–8170 prior to collecting specimen. |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Specimens must arrive in the laboratory before 1600.• Store as whole blood or bone marrow in original tube at room temperature.• Submit specimen with a completed Hematopathology Requisition (HNL–05) Form. Clinical history, diagnosis, and specimen type are required.• Form can be requested by contacting our Customer Care Department at 610–402–8170. |
| Reference Range: | See Patient Report |
| Clinical Utility: | Immunophenotyping by flow cytometry distinguishes among various hematopoietic cell populations and determines the degree of expression of a panel of cell surface antigens. The test is used along with morphologic, cytogenetic, and molecular genetic analysis in the identification/classification of hematopoietic neoplasms (leukemia, lymphoma, myelodysplastic disorders). |

| Test Name | Order Code |
|--|--|
| Leukemia/Lymphoma Profile, Tissue/Fluid, Flow Cytometry | LYTPR |
| Includes: | Flow cytometry markers appropriate for the clinical presentation |
| Suggest CPT coding: | 88184,88185(x18) |
| Methodology: | Flow Cytometry |
| Testing Schedule: | Routine, Monday–Friday no holidays |
| Report Available: | 2–4 days |
| Minimum Volume: | 2 mL tissue OR fluid |

Continued...

| Test Name | Order Code |
|--|---|
| Leukemia/Lymphoma Profile, Tissue/Fluid, Flow Cytometry | LYTPR |
| Container: | <ul style="list-style-type: none">• Submit tissue in an RPMI media.• Submit fluid in sterile conical tube. |
| Collection: | <ul style="list-style-type: none">• Collect Monday–Friday only before 1400, no holidays.• For special requests contact our Customer Care Department at 610–402–8170 prior to collecting specimen. |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Specimens must arrive in the laboratory before 1600.• Submit specimen with a completed Hematopathology Requisition (HNL–05) Form and include clinical history, diagnosis, and specimen type.• Form and RPMI Media can be requested by contacting our Customer Care Department at 610–402–8170. |
| Reference Range: | See Patient Report |
| Clinical Utility: | Immunophenotyping by flow cytometry distinguishes among various hematopoietic cell populations and determines the degree of expression of a panel of cell surface antigens. The test is used along with morphologic, cytogenetic, and molecular genetic analysis in the identification/classification of hematopoietic neoplasms (leukemia, lymphoma, myelodysplastic disorders). |

| Test Name | Order Code |
|--|---|
| Lipid Panel | LIPAN |
| Includes: | <ul style="list-style-type: none">• Cholesterol, Total• Triglycerides• HDL Cholesterol, Direct• Non–HDL Cholesterol• LDL Cholesterol, Calculated• Cholesterol/HDL Ratio |
| Suggest CPT coding: | 80061 |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine, daily |
| Report Available: | 1 day |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Collection: | Patient should fast for 12–14 hours (nothing by mouth except water and any essential medications). |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Patient should discontinue use of drugs, if possible, for 3–4 weeks prior to testing and should be maintaining a stable weight, considered normal, for a least 1 week.• Wait 4–8 weeks after a myocardial infarction or a traumatic episode. |

Continued...

| Test Name | Order Code |
|--------------------------|---|
| Lipid Panel | LIPAN |
| Reference Range: | See individual test listings. |
| | Reference Ranges for Calculated Parameters (NCEP Adult Treatment Panel III guidelines) |
| | NON-HDL Cholesterol |
| | <ul style="list-style-type: none">• Very High/Highest risk patient (known CVD, diabetes with elevated risk): <130 mg/dL, optional goal: <100 mg/dL• High Risk Patient, CHD-risk equivalent, (Framingham 10 year risk score >20%/10y, diabetes without other major risk factors): <130 mg/dL• Moderately-high/intermediate risk patient (>2 major CVD risk factors, Framingham 10-year risk score from 10-20%): <160 mg/dL, optional goal: <130 mg/dL |
| | LDL Cholesterol, Calculated |
| | <ul style="list-style-type: none">• Near/above optimal: 100-129 mg/dL• Borderline high: 130 - 159 mg/dL• High: 160 - 189 mg/dL• Very High: >190 mg/dL |
| | CHOL/HDL Ratio Relative Risk: |
| | <ul style="list-style-type: none">• 1/2 Average Risk 3.43• Average Risk 4.97• 2x Average Risk 9.55• 3x Average Risk 23.39 |
| | The calculation of LDL by the Freidewald formula becomes invalid when the Triglyceride level is > 400 mg/dL. |
| Clinical Utility: | Useful for cardiovascular risk assessment. |

| Test Name | Order Code |
|--|---|
| Lipid Profile with LDL | LIPLD |
| Includes: | <ul style="list-style-type: none">• Cholesterol, Total• Triglyceride• HDL Cholesterol• Non-HDL Cholesterol• LDL Cholesterol, Direct• Cholesterol/HDL Ratio |
| Suggest CPT coding: | 80061,83721 |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine, daily |
| Report Available: | 1 day |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Collection: | Patient should fast for 12-14 hours (nothing by mouth except water and any essential medications). |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Patient should discontinue use of drugs, if possible, for 3-4 weeks prior to testing and should be maintaining a stable weight, considered normal, for a least 1 week.• Wait 4-8 weeks after a myocardial infarction or a traumatic episode. |
| Reference Range: | See individual test listings and order code LIPLD. |

Continued...

| Test Name | Order Code |
|-------------------------------|--|
| Lipid Profile with LDL | LIPLD |
| Clinical Utility: | Useful for cardiocascular risk assessment. |

| Test Name | Order Code |
|-----------------------------|--|
| Liver Function Panel | LFP |
| Includes: | <ul style="list-style-type: none">• Alanine Aminotransferase (ALT)• Albumin• Alkaline phosphatase• Aspartate Aminotransferase (AST)• Bilirubin, Direct• Bilirubin, Total• Protein, Total |
| Suggest CPT coding: | 80076 |
| Methodology: | See individual test listings. |
| Testing Schedule: | Routine daily, STAT testing available |
| Report Available: | 1 day |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listing. |
| Critical Values: | See individual test listing. |
| Clinical Utility: | Used in the evaluation of hepatic function and hepatic disorders. |

| Test Name | Order Code |
|---------------------------------------|--|
| Liver Function Panel, Neonatal | NLFP |
| Includes: | <ul style="list-style-type: none">• Alanine Aminotransferase (ALT)• Albumin• Alkaline Phosphatase• Aspartate Aminotransferase (AST)• Bilirubin, Direct Neonatal• Bilirubin, Total Neonatal• Protein, Total |
| Suggest CPT coding: | 80076 |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine daily, STAT testing available |
| Report Available: | 1 day |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listing. |
| Critical Values: | See individual test listing |
| Clinical Utility: | Used in the evaluation of hepatic function and hepatic disorders of the newborn. |

| Test Name | Order Code |
|--|---|
| Lyme Disease Antibody Profile | LYMEP |
| Includes: | <ul style="list-style-type: none"> Lyme Antibody, Total (IgG/IgM) Lyme Antibody, IgM Reflexed when appropriate <ul style="list-style-type: none"> Lyme Antibody, Western Blot IgG Lyme Antibody, Western Blot IgM |
| Suggest CPT coding: | 86618(x2) |
| Methodology: | Enzyme Linked Immunosorbent Assay (ELISA) |
| Testing Schedule: | Routine, 3 times per week |
| Report Available: | 3–7 days |
| Minimum Volume: | 2 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | The Department of Health requires mandatory reporting of any confirmed positive result. |
| Reference Range: | <0.91 |
| Clinical Utility: | This test is used as a screen for assessment of exposure to <i>B. burgdorferi</i> during early- and late-stage disease. All IgM and IgG EIA positive results are confirmed by Western Blot. |

| Test Name | Order Code |
|--|---|
| Lymphocyte Subset Profile | LSUBP |
| Includes: | <ul style="list-style-type: none"> CD45 Total Lymph Count Absolute and % B cells (CD19) Absolute and % T cells (CD3) Absolute and % Helper cells (CD4) Absolute and % suppressor cells (CD8) Helper/Suppressor Ratio (CD4/CD8 Ratio) Absolute and % NK cells (CD3–CD56+) |
| Suggest CPT coding: | 86355,86357,86359,86360 |
| Methodology: | Flow Cytometry |
| Testing Schedule: | Routine, Monday– Friday no holidays |
| Report Available: | 2–4 days |
| Minimum Volume: | 0.5 mL whole blood |
| Container: | Lavender top tube, <u>EDTA</u> |
| Special Instructions and/or Comments: | <ul style="list-style-type: none"> Call laboratory for holiday collection instructions. Store as whole blood in original tube at room temperature. The Department of Health requires mandatory reporting of any abnormal CD4 result. |
| Reference Range: | See Patient Report. |
| Clinical Utility: | Monitor patient's individual T, B, and NK cell populations to infer cellular and humoral immune status. |

| Test Name | Order Code |
|---|--|
| Mycoplasma pneumoniae Antibody Profile | MYCP |
| Includes: | Mycoplasma pneumoniae IgG and IgM antibodies |
| Suggest CPT coding: | 86738(x2) |
| Methodology: | Enzyme-Linked Immunosorbent Assay (ELISA) |
| Testing Schedule: | Routine, 2 times per week |

Continued...

| Test Name | | Order Code | | | | | | | | | | | | | | | |
|---|---|---|-----|----------------|---|---|---|---|---|--|---|---|---|---|---|---|--|
| Mycoplasma pneumoniae Antibody Profile | | MYCP | | | | | | | | | | | | | | | |
| Report Available: | 4–7 days | | | | | | | | | | | | | | | | |
| Specimen Requirements: | Reference Range See table Mycoplasma Profile Interpretation Chart | | | | | | | | | | | | | | | | |
| | <table border="1"> <thead> <tr> <th>IgG</th> <th>IgM</th> <th>Interpretation</th> </tr> </thead> <tbody> <tr> <td>N</td> <td>N</td> <td>No serological evidence of recent or past Mycoplasma pneumoniae infection. Consideration of symptom onset with time of testing is important. A follow-up “convalescent” specimen may be warranted if results do not correlate with clinical presentation.</td> </tr> <tr> <td>N</td> <td>P</td> <td>Suggest very early “acute” primary infection. This pattern warrants a second specimen to document seroconversion. Repeat testing in 10–14 days is suggested.</td> </tr> <tr> <td>P</td> <td>P</td> <td>Suggests current or recent infection with Mycoplasma pneumoniae. Results should be interpreted in light of clinical presentation.</td> </tr> <tr> <td>P</td> <td>N</td> <td>Suggests past infection with Mycoplasma pneumoniae.</td> </tr> </tbody> </table> | IgG | IgM | Interpretation | N | N | No serological evidence of recent or past Mycoplasma pneumoniae infection. Consideration of symptom onset with time of testing is important. A follow-up “convalescent” specimen may be warranted if results do not correlate with clinical presentation. | N | P | Suggest very early “acute” primary infection. This pattern warrants a second specimen to document seroconversion. Repeat testing in 10–14 days is suggested. | P | P | Suggests current or recent infection with Mycoplasma pneumoniae. Results should be interpreted in light of clinical presentation. | P | N | Suggests past infection with Mycoplasma pneumoniae. | |
| IgG | IgM | Interpretation | | | | | | | | | | | | | | | |
| N | N | No serological evidence of recent or past Mycoplasma pneumoniae infection. Consideration of symptom onset with time of testing is important. A follow-up “convalescent” specimen may be warranted if results do not correlate with clinical presentation. | | | | | | | | | | | | | | | |
| N | P | Suggest very early “acute” primary infection. This pattern warrants a second specimen to document seroconversion. Repeat testing in 10–14 days is suggested. | | | | | | | | | | | | | | | |
| P | P | Suggests current or recent infection with Mycoplasma pneumoniae. Results should be interpreted in light of clinical presentation. | | | | | | | | | | | | | | | |
| P | N | Suggests past infection with Mycoplasma pneumoniae. | | | | | | | | | | | | | | | |
| | Clinical Utility: Evaluation of current or recent infection with Mycoplasma pneumoniae. | | | | | | | | | | | | | | | | |
| Minimum Volume: | 1 mL serum | | | | | | | | | | | | | | | | |
| Container: | Gold top tube, <u>serum separator</u> | | | | | | | | | | | | | | | | |
| Reference Range: | <0.91 | | | | | | | | | | | | | | | | |
| Clinical Utility: | Evaluation of current or recent infection with Mycoplasma pneumoniae. | | | | | | | | | | | | | | | | |

| Test Name | | Order Code |
|----------------------------|--|-------------------|
| Obstetric Panel | | PN1 |
| Includes: | <ul style="list-style-type: none"> • ABO/Rh and Antibody Screen (PREN code–ordered separately) • CBC with Automated Differential (CBCD) • Hepatitis B Surface Antigen (HbsAg) • Rubella IgG Antibody, Immune Status (RUBG) • RPR • Reflexed when appropriate: <ul style="list-style-type: none"> Hepatitis B Surface Antigen Neutralization Syphilis Serology RPR Titer Antibody Identification Phenotype Antigen Test Direct Antiglobulin Test Antibody Elution Antibody Titer | |
| Suggest CPT coding: | 80055 | |
| Methodology: | See individual test listings. | |
| Testing Schedule: | Routine, daily | |

Continued...

| Test Name | Order Code |
|--|--|
| Obstetric Panel | PN1 |
| Report Available: | 1–3 days |
| Container: | 2 Gold top tubes, <u>serum separator</u> , AND 1 lavender top tube, <u>EDTA</u> AND 1 pink top tube, <u>EDTA</u> |
| Special Instructions and/or Comments: | <ul style="list-style-type: none">• Submit specimen with a completed Blood Bank Requisition (LAB-04) Form.• This test should be performed on all pregnant women as early in pregnancy as possible.• For all clinically significant antibodies having reactivity greater or equal to 1+, an initial antibody titer will be performed. Subsequent titers should be requested by the physician.• Rh (D) positive women should have a repeat Prenatal Testing performed when there is a history of clinically significant red cell antibodies, previous blood transfusions, or trauma to the abdomen.• Rh (D) negative women should have a repeat Prenatal Testing performed at 28–30 weeks gestation prior to Rh (D) Immune Globulin (RhIG) administration and when other indications exist (see Rh (D) Immune Globulin for additional information)• Request an Obstetric Profile, Repeat Blood Bank Only if required. |
| Reference Range: | See individual test listings. |
| Critical Values: | See individual test listings. |
| Clinical Utility: | See individual test listings. |

| Test Name | Order Code |
|---|---|
| Obstetric Profile PREN with Urinalysis | PN2 |
| Includes: | <ul style="list-style-type: none">• ABO/Rh and Antibody Screen (PREN code–ordered separately)• CBC with Differential (CBCD)• Hepatitis B surface Antigen (HbsAg)• Rubella IgG Antibody, Immune Status (RUBG)• Urinalysis• RPR• Reflexed when appropriate:<ul style="list-style-type: none">• Hepatitis B Surface Antigen Neutralization• Syphilis Serology• RPR Titer• Antibody Identification• Phenotype Antigen Test• Direct Antiglobulin Test• Antibody Elution• Antibody Titer |
| Suggest CPT coding: | 80055,81001 |
| Methodology: | See individual test listings. |
| Testing Schedule: | Routine, daily |
| Report Available: | 1–3 days |
| Container: | 2 Gold top tubes, <u>serum separator</u> , AND 1 Lavender top tube, <u>EDTA</u> , AND 1 Pink top tube, <u>EDTA</u> AND 1 plastic urine container |
| Reference Range: | See individual test listings. |
| Critical Values: | See individual test listings. |
| Clinical Utility: | See individual test listings. |

| Test Name | Order Code |
|---|---|
| Parainfluenza Virus Antibody Profile | PAVA |
| Includes: | Parainfluenza Virus 1, 2 and 3 antibodies |

Continued...

| Test Name | Order Code | | | | |
|--|---|-------|----------------------|-------|-------------------|
| Parainfluenza Virus Antibody Profile | PAVA | | | | |
| Suggest CPT coding: | 86790(x3) | | | | |
| Methodology: | Complement Fixation | | | | |
| Testing Schedule: | Routine, Monday–Friday, no holidays | | | | |
| Report Available: | 5–7 days | | | | |
| Minimum Volume: | 1 mL serum | | | | |
| Container: | Gold top tube, <u>serum separator</u> | | | | |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. | | | | |
| Reference Range: | <table border="1"><tr><td>< 1:8</td><td>No antibody detected</td></tr><tr><td>≥ 1:8</td><td>Antibody detected</td></tr></table> | < 1:8 | No antibody detected | ≥ 1:8 | Antibody detected |
| < 1:8 | No antibody detected | | | | |
| ≥ 1:8 | Antibody detected | | | | |
| Clinical Utility: | Single titers of ≥ 1.64 are indicative of recent infection. Titers of 1:8 to 1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four fold increase or greater in titer between acute and convalescent specimens confirms the diagnosis. After initial infection, antibody responses at a later date are often heterotypic and exhibit cross reactivity with other paramyxoviruses (eg. mumps). | | | | |

| Test Name | Order Code |
|--|--|
| Poliovirus Antibody Profile | POVA |
| Includes: | Poliovirus 1, 2 and 3 Antibodies NOTE: Use this test to access recent exposure to poliovirus. For vaccine response see Poliovirus Antibody, Vaccine Response (POLVR) |
| Suggest CPT coding: | 86658(x3) |
| Methodology: | Complement Fixation |
| Testing Schedule: | Routine, 3 times per week |
| Report Available: | 7–10 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. |
| Reference Range: | <1:8 Antibody not detected. ≥1:8 Antibody detected |
| Clinical Utility: | This assay is designed to detect recent poliovirus infection; single titers $\geq 1:32$ provide strong support for recent natural (non–vaccine) exposure. The test is not appropriate for assessing vaccine responses or immunity to polioviruses; poliovirus neutralization is the recommended test for these purposes (POLVR). |

| Test Name | Order Code |
|-----------------------------|---|
| Renal Function Panel | RFP |
| Includes: | <ul style="list-style-type: none"> • Albumin • Calcium • Carbon Dioxide (CO2) • Chloride • Creatinine • Glucose • Phosphorous • Potassium • Sodium • Urea Nitrogen (BUN) • Anion Gap Calculation • Glomerular Filtration Rate Calculation (GFR) |
| Suggest CPT coding: | 80069 |
| Methodology: | See individual test listings. |
| Testing Schedule: | Routine daily, STAT testing available |
| Report Available: | 1 day |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listings |
| Critical Values: | See individual test listings |
| Clinical Utility: | Used in the evaluation of renal function and renal disorders. |

| Test Name | Order Code |
|---------------------------------|---------------------------------------|
| Rubella Antibody Profile | RUBP |
| Includes: | Rubella virus IgG and IgM antibodies |
| Suggest CPT coding: | 86762(x2) |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine, 1 time per week |
| Report Available: | 4-7 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |

Continued...

| Test Name Rubella Antibody Profile | | Order Code RUBP |
|--|--|---|
| Reference Range: | See individual test listings and the following table. | |
| | Rubella Profile Interpretation | |
| | IgG | IgM |
| | Negative | Negative |
| | Negative | Positive |
| | Positive | Positive |
| | Positive | Negative |
| | | Comment |
| | | No detectable antibody to Rubella virus and suggests no current, recent, or past infection. Patient is not immune and is susceptible to primary infection. |
| | | May suggest very early "acute" infection with Rubella virus or recent vaccination. This pattern warrants a second specimen to document seroconversion as well as rule out possible cross-reactive antibodies. |
| | | Suggests current or recent primary infection with Rubella virus. Patients may continue to produce Rubella specific IgM antibody for 1-6 months following a primary infection. On the basis of these results, it is not possible to distinguish the difference between vaccine induced antibody and antibody resulting from natural infection. Results should be interpreted in light of the clinical situation. |
| | | Suggests either past exposure to or vaccination with Rubella virus. Patient is immune. |
| Clinical Utility: | For the in vitro detection of IgG & IgM antibodies specific for Rubella. | |

| Test Name Sjögren's Autoantibody Profile | | Order Code SJO |
|--|---|--------------------------|
| Includes: | SSA and SSB Autoantibodies | |
| Suggest CPT coding: | 86235(x2) | |
| Methodology: | Enzyme-Linked Immunosorbent Assay (ELISA) | |
| Testing Schedule: | Routine, 1 time per week | |
| Report Available: | 4-7 days | |
| Minimum Volume: | 1 mL serum | |
| Container: | Gold top tube, <u>serum separator</u> | |
| Reference Range: | <20 U/mL | |
| Clinical Utility: | This panel is used to aid the diagnosis of Sjogren's Syndrome. One or both of the autoantibodies are detected in 80-90% of Sjogren's Syndrome (SS) and 30 - 35% of patients with SLE. SSA and SSB antibodies detected in 96% of patients with primary (SS) and in all patients with SS secondary to RA. SSA and SSB are rarely detected in SS secondary to rheumatoid arthritis, progressive systemic sclerosis, and primary biliary cirrhosis. | |

| Test Name | Order Code |
|-------------------------------|--|
| Synovial Fluid Profile | SSFA |
| Includes: | <ul style="list-style-type: none"> • Cell Count • Crystals • Mucin Clot • Viscosity |
| Suggest CPT coding: | 83872,85810,89050,89060 |
| Methodology: | Manual |
| Testing Schedule: | Routine daily, STAT testing available |
| Report Available: | 1 day |
| Minimum Volume: | See individual test listings. |
| Container: | Lavender top tube, <u>EDTA</u> AND Red top tube, <u>no serum separator</u> |
| Reference Range: | See individual test listings |
| Clinical Utility: | Used in the evaluation of inflammatory and infectious disorders of joints and in the evaluation of joint pathology and trauma. |

| Test Name | Order Code |
|------------------------------------|---|
| Thoracentesis Fluid Profile | TFA |
| Includes: | <ul style="list-style-type: none"> • Cell count • Glucose, Fluid • Lactate Dehydrogenase, Fluid • Protein, Total, Fluid |
| Suggest CPT coding: | 82945,83615,84157,89050 |
| Methodology: | See individual test listings. |
| Testing Schedule: | Routine daily, STAT testing available |
| Report Available: | 1 day |
| Minimum Volume: | 2 mL thoracentesis fluid in each tube |
| Container: | Red top tube, <u>no serum separator</u> AND Lavender top tube, <u>EDTA</u> |
| Reference Range: | See individual test listing |
| Clinical Utility: | Used to evaluate effusion and differentiate exudate from transudate. |

| Test Name | Order Code |
|--|---|
| Thyroglobulin Profile | THGLB |
| Includes: | <ul style="list-style-type: none"> • Thyroglobulin, Quantitative • Thyroglobulin Autoantibody |
| Suggest CPT coding: | 84432,86800 |
| Methodology: | Chemiluminescent Immunoassay |
| Testing Schedule: | Routine, 3 times per week |
| Report Available: | 4-7 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | Centrifuge, transfer to plastic aliquot tube and refrigerate. |

Continued...

| Test Name | Order Code | | | | | | | | |
|------------------------------------|---|------------------------------------|--|-----------------|------------|---------------------|-----------|-----------------------------------|-------------|
| Thyroglobulin Profile | THGLB | | | | | | | | |
| Reference Range: | | | | | | | | | |
| | <table border="1"><thead><tr><th colspan="2">Thyroglobulin, Quantitative</th></tr></thead><tbody><tr><td>Normal Thyroid:</td><td>< 33 ng/mL</td></tr><tr><td>Athyroidic Patient:</td><td>< 5 ng/mL</td></tr><tr><td>Thyroglobulin Autoantibody</td><td>< 2.3 IU/mL</td></tr></tbody></table> | Thyroglobulin, Quantitative | | Normal Thyroid: | < 33 ng/mL | Athyroidic Patient: | < 5 ng/mL | Thyroglobulin Autoantibody | < 2.3 IU/mL |
| Thyroglobulin, Quantitative | | | | | | | | | |
| Normal Thyroid: | < 33 ng/mL | | | | | | | | |
| Athyroidic Patient: | < 5 ng/mL | | | | | | | | |
| Thyroglobulin Autoantibody | < 2.3 IU/mL | | | | | | | | |
| Clinical Utility: | Thyroglobulin testing is often used as a tumor marker to determine the effectiveness of thyroid cancer treatment. | | | | | | | | |

| Test Name | Order Code |
|-----------------------------------|---|
| TORCH IgM Antibody Profile | TORCM |
| Includes: | IgM Antibodies to each of the following: <ul style="list-style-type: none">• Toxoplasma gondii• Rubella virus• Cytomegalovirus (CMV)• Herpes Simplex Virus (HSV) types 1 and 2 |
| Suggest CPT coding: | 86645,86695,86696,86762,86778 |
| Methodology: | See individual test listings. |
| Testing Schedule: | Routine, 2 times per week |
| Report Available: | 4–7 days |
| Minimum Volume: | 2 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listings. |
| Clinical Utility: | Aid in diagnosis of acute or recent infection. |

| Test Name | Order Code | | | | |
|--|--|------------------------------------|---------------|--------------------|--------|
| Total Iron Binding Capacity Profile | TIBCP | | | | |
| Includes: | <ul style="list-style-type: none">• Iron, Serum• Transferrin• Calculation of Percent Saturation and TIBC | | | | |
| Suggest CPT coding: | 83540,84466 | | | | |
| Methodology: | See individual test listings. | | | | |
| Testing Schedule: | Routine, daily | | | | |
| Report Available: | 1 day | | | | |
| Minimum Volume: | 1 mL serum | | | | |
| Container: | Gold top tube, <u>serum separator</u> | | | | |
| Collection: | <ul style="list-style-type: none">• Specimen should be collected prior to therapeutic iron dose or blood transfusion.• Iron determinations on patients who have had blood transfusions should be delayed for at least 4 days. | | | | |
| Reference Range: | See individual test listings. | | | | |
| | <table border="1"><tbody><tr><td>Total iron binding capacity (TIBC)</td><td>260–430 mg/mL</td></tr><tr><td>Percent saturation</td><td>20–50%</td></tr></tbody></table> | Total iron binding capacity (TIBC) | 260–430 mg/mL | Percent saturation | 20–50% |
| Total iron binding capacity (TIBC) | 260–430 mg/mL | | | | |
| Percent saturation | 20–50% | | | | |

Continued...

| Test Name | Order Code |
|--|--|
| Total Iron Binding Capacity Profile | TIBCP |
| Clinical Utility: | Increased total iron binding capacity is often seen in iron deficiency states, parental iron administration, pregnancy without iron supplements, and hepatitis or hepatic necrosis. Decreased concentrations are often seen in chronic inflammatory disorders, chronic iron overloading, and malignancies. |

| Test Name | Order Code |
|--|---|
| Toxic Shock Antibody Profile | TSSN |
| Includes: | TSST-1 antibody/Enterotoxin B antibody |
| Suggest CPT coding: | 86609(x2) |
| Methodology: | MAID (Multi-Analyte Immunodetection) |
| Testing Schedule: | Routine, 1 time per week |
| Report Available: | 7-10 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. |
| Reference Range: | Negative |
| Clinical Utility: | Toxic shock syndrome (TSS) is associated with strains of Staphylococcus aureus that produce TSS toxin-1 (TSST-1) and/or staphylococcal enterotoxin B (SEB). TSST-1 is associated with approximately 65% of TSS cases, whereas SEB is associated with approximately 20% of cases. Individuals lacking antibodies to TSST-1 or to SEB (approximately 10% and 20% of adults respectively) are presumed to be at highest risk of TSS. This test is thus designed to identify antibody-negative individuals at risk for TSS; it should not be used as a tool for diagnosing TSS. |

| Test Name | Order Code |
|------------------------------------|---|
| Toxoplasma Antibody Profile | TOXP |
| Includes: | Toxoplasma gondii IgG and IgM antibodies. |
| Suggest CPT coding: | 86777,86778 |
| Methodology: | See individual test listings. |
| Testing Schedule: | Routine, 2 times per week |
| Report Available: | 4-7 days |
| Minimum Volume: | 1 mL serum |
| Container: | Gold top tube, <u>serum separator</u> |
| Reference Range: | See individual test listing. |
| Clinical Utility: | Support the serodiagnosis of toxoplasmosis. |

| Test Name | Order Code |
|--|---|
| von Willebrand Profile, Comprehensive | VWD |
| Includes: | <ul style="list-style-type: none">Factor VIII ActivityFactor VIII AntigenRistocetin CofactorInterpretation |
| Suggest CPT coding: | 85240,85245,85246 |

Continued...

| Test Name | Order Code |
|--|---|
| von Willebrand Profile, Comprehensive | VWD |
| Methodology: | See individual test listings |
| Testing Schedule: | Routine, 1 time per week |
| Report Available: | 7–10 days |
| Minimum Volume: | 4 mL plasma |
| Container: | 4 Full Light Blue top tubes, <u>sodium citrate</u> |
| Collection: | See Special Handling Instructions for “Coagulation Studies”, listed under the Specimen Collection, Preparation, and Handling Section |
| Special Instructions and/or Comments: | <ul style="list-style-type: none"> • Transport all tubes at room temperature and deliver immediately to the testing department. • DO NOT chill; platelets are activated at low temperatures. • DO NOT centrifuge or aliquot; must remain as whole blood in original tubes. |
| Reference Range: | See individual test listings |
| Clinical Utility: | See individual test listings |

| Test Name | Order Code | | | | |
|--|---|-------------------------------|--------------|-------------------------------|--------------|
| West Nile Virus Antibody Profile | WNVS | | | | |
| Includes: | IgG and IgM Antibodies | | | | |
| Suggest CPT coding: | 86788,86789 | | | | |
| Methodology: | West Nile Virus IgG: Enzyme Immunoassay (EIA) West Nile Virus IgM: MAC EIA–IgM Antibody Capture EIA | | | | |
| Testing Schedule: | Routine, 2 times per week | | | | |
| Report Available: | 5–7 days | | | | |
| Minimum Volume: | 1 mL serum | | | | |
| Container: | Gold top tube, <u>serum separator</u> | | | | |
| Collection: | Convalescent specimens, if required, should be submitted at least 2 weeks after the acute specimen. | | | | |
| Special Instructions and/or Comments: | Centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate. | | | | |
| Reference Range: | <table border="1" style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td style="padding: 2px;">West Nile Virus IgG Antibody:</td> <td style="padding: 2px;">< 1.30 INDEX</td> </tr> <tr> <td style="padding: 2px;">West Nile Virus IgM Antibody:</td> <td style="padding: 2px;">< 0.90 INDEX</td> </tr> </tbody> </table> | West Nile Virus IgG Antibody: | < 1.30 INDEX | West Nile Virus IgM Antibody: | < 0.90 INDEX |
| West Nile Virus IgG Antibody: | < 1.30 INDEX | | | | |
| West Nile Virus IgM Antibody: | < 0.90 INDEX | | | | |
| Clinical Utility: | The West Nile Virus is a single–stranded RNA virus of the Flaviviridae family. Like other arboviruses (e.g. St. Louis Encephalitis, Dengue Fever, and Yellow Fever), its main route of transmission to humans is through mosquitoes (primarily culex species) that have acquired the virus from infected birds. A single elevated WNV result, including IgM that may persist for many months, could represent past infection with WNV of infection with another flavivirus including Dengue and St. Louis Encephalitis. Diagnosis of suspected WNV infection is confirmed by isolation of WNV or detection of WNV antigen or nucleic acid sequences in clinical samples or detection of WNV–specific IgM in blood or spinal fluid, confirmed with detection of WNV–specific neutralizing antibody in the same or a subsequent sample. | | | | |